Table 1.
Study patients: demography and baseline characteristics (all patients)
| Dose group Dose [spheroids/cm2] |
Low | Medium | High | All patients |
|---|---|---|---|---|
| 3–7 | 10–30 | 40–70 | ||
| N = 25 | N = 25 | N = 25 | N = 75 | |
| Sex | ||||
| Female | 8 | 4 | 10 | 22 |
| Male | 17 | 21 | 15 | 53 |
| Age [years] | 33 ± 10 | 34 ± 9 | 34 ± 9 | 34 ± 9 |
| BMI | ||||
| [kg/m2] | 24.9 ± 2.5 | 25.6 ± 3.2 | 25.1 ± 3.6 | 25.2 ± 3.1 |
| Range | 21.3–29.8 | 19.4–33.2 | 19.0–32.3 | 19.0–33.2 |
| Defect size | ||||
| [cm2] | 4.8 ± 1.5 | 4.9 ± 1.3 | 5.2 ± 1.3 | 5.0 ± 1.9 |
| Range | 0.5a–7.5 | 1.3a–7.5 | 3.0a–8.0 | 0.5a–8.0 |
| Defect size group | ||||
| 4–6.99 cm2 | 22 | 22 | 21 | 65 |
| 7–10 cm2 | 3 | 3 | 4 | 10 |
| Defect location (primary) | ||||
| Femur | 9 | 10 | 9 | 28 |
| Tibia | – | – | – | – |
| Patella | 16 | 15 | 16 | 47 |
Numbers of patients or mean ± SD, or where appropriate the range (minimum–maximum), are given
aValue outside allowed range